Marker Therapeutics (MRKR) Short-Term Debt issuances (2012 - 2016)

Marker Therapeutics (MRKR) reported Short-Term Debt issuances of -$25000.0 for Q1 2016, down 5100.0% quarter-over-quarter from $500.0 in Q1 2014.

Marker Therapeutics (MRKR) Short-Term Debt issuances (2012 - 2016) Analysis & Trends

Marker Therapeutics (MRKR) has 3 years of Short-Term Debt issuances data on file, last reported at -$25000.0 in Q1 2016.

Short-Term Debt issuances for Q1 2016 came in at -$25000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was -$25000.0 (down 5100.0% YoY), and the FY2016 annual result was -$25000.0, changed N/A from the prior year.
Short-Term Debt issuances retreated to -$25000.0 in Q1 2016 per MRKR's latest filing, from $500.0 in the prior quarter.
Over five years, Short-Term Debt issuances peaked at $3000.0 in Q3 2012 and troughed at -$25000.0 in Q1 2016.
A 3-year average of -$9875.0 and a median of -$8750.0 in 2012 frame the typical range for Short-Term Debt issuances.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ST Debt Issuance (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-33,000.00
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Marker Therapeutics	28.20 Mn	28.20 Mn	-	-

Download Data